Walgreens’ VillageMD Bet: A Healthcare Roll-Up That Scaled Before It Proved Itself

The Walgreens VillageMD healthcare roll-up in brief

Walgreens wanted its pharmacies to become a front door to American healthcare. It paid $5.2 billion for control of VillageMD in 2021, then helped fund VillageMD’s $8.9 billion purchase of Summit Health-CityMD. The result was a healthcare roll-up of primary care, specialty care and urgent care, owned by a pharmacy chain.

About two years after the second deal, clinics were closing and Walgreens had recorded $15.4 billion of goodwill impairments tied to VillageMD. In August 2025, Sycamore Partners took Walgreens private and split it into five standalone companies. VillageMD was one of them, and it is now being sold off in pieces.

The idea was not irrational. Pharmacy, physicians and value-based contracts can reinforce each other. The problem was the order of operations: Walgreens paid for national scale before it had proven the economics of a single clinic.

Three deals in 30 months

The relationship started small. In July 2020, Walgreens agreed to invest $1 billion so VillageMD could open 500 to 700 doctor offices in Walgreens stores within five years.

Fifteen months later, the plan grew. Walgreens agreed to a $5.2 billion investment that lifted its stake from 30% to 63%, with a target of 600 practices by 2025 and 1,000 by 2027. About $2.3 billion of the price bought newly issued units; the rest bought out existing holders.

A year after that, VillageMD agreed to buy Summit Health-CityMD for $8.9 billion including debt. Walgreens put in $3.5 billion, split between debt and equity, and Cigna’s Evernorth joined as a minority owner. Walgreens’ stake fell to 53% even as its money at risk rose.

Each step raised the stakes on assumptions the previous step had not yet tested. In any healthcare roll-up, that is the moment for a hard stop, and for acquisition strategy to ask whether the base unit works before anyone prices the next deal.

What the healthcare roll-up was priced for

Purchase accounting shows how much of the value rested on the future. Walgreens booked the VillageMD control deal at a total value of $10.05 billion, with $8.17 billion of goodwill. That is 81%. Summit added $8.83 billion, with $5.46 billion of goodwill, or 62%.

These are accounting values, not Walgreens’ cash. They include earlier stakes, other owners and assumed debt. The pattern still matters. When about 72% of $18.9 billion sits in goodwill, the price depends almost entirely on future clinic economics and pharmacy synergy.

A buy-side model can separate those layers. Financial due diligence should show what a clinic earns once its patient panel matures, and how many clinics have reached that point. A clinic opened in 2021 had little time to get there before the Summit deal was signed.

The clinic math never caught up

The target kept rising while the build lagged. By April 2024, Walgreens was closing about 160 VillageMD locations. By the time Sycamore bought Walgreens, there were around 90 Village Medical at Walgreens clinics, against a goal of 1,000.

In a healthcare roll-up built on primary care, the unit is slower to mature and more local than pharmacy retail. Physicians, not store sites, were the scarce asset. Recruiting and keeping them is a people problem, which is why HR due diligence and HR integration matter as much as the lease schedule.

Closures destroy more than leases. They strand the recruiting, patient acquisition and payer relationships built into each site. The accounting followed:

The attributable figures, from the fiscal 2024 and second-quarter fiscal 2025 results, are after tax and after the share owned by others. Neither is cash lost, but each goodwill impairment is a verdict on the price paid.

Walgreens paid for nationwide scale, mature clinics and pharmacy synergy while all three were still a forecast.

How the healthcare roll-up unwound

Sycamore completed its purchase of Walgreens on August 28, 2025. Shareholders received $11.45 a share in cash plus a non-transferable right to up to $3.00 more from future sales of Walgreens’ debt and equity interests in VillageMD.

Walgreens, Boots, Shields Health Solutions, CareCentrix and VillageMD became separate standalone companies. The split reversed the integration thesis that had justified putting them together.

VillageMD is now being sold region by region. Harbor Health bought 32 Texas clinics in September 2025, and in October 2026 agreed to buy 27 more around Houston, closing at year end. VillageMD still had 17 clinics in Georgia, two in Kentucky and 12 Houston practices outside that deal.

The legal tail continues. In January 2026, a judge let part of a securities suit by investors over the Walgreens VillageMD partnership move forward.

Selling locally may recover more value, because local buyers bring payer contracts and referral networks. That is its own lesson: physician platform value lives in people and local relationships, not standardized boxes.

Private equity on both sides

Private equity sat on both ends of this healthcare roll-up. Warburg Pincus had backed CityMD since 2017 and helped form Summit Health-CityMD in 2019. It exited in the $8.9 billion sale to VillageMD, selling a scaled physician platform to a strategic buyer that also paid for the integration story.

Sycamore came in at the other end and valued the parts separately. A seller’s best moment was a buyer’s riskiest one. For sponsors building their own platforms, the question is which side of that trade the next add-on puts you on.

Culture belongs in that answer. Folding independent physician groups into a retailer’s operating model is the kind of clash that explains why most integrations fail on culture.

Four gates before the next healthcare roll-up add-on

The core lesson: a strategically sound platform can still destroy value when the buyer pays today for integration benefits it has not yet learned to produce.

Most sponsors will never write a check this size. The mechanics of a healthcare roll-up still apply to any platform buying its second or third add-on. Before the next deal, each gate should be passed on evidence, not momentum.

Gate 3 is where commercial due diligence earns its fee: payer contracts and referral flows decide whether a clinic ever reaches maturity.

The same measures should become the integration scorecard. When buy-side diligence and post-merger integration track one set of numbers, and a 100-day plan sets the baseline, the next acquisition is decided on data.

Finance has to own that baseline. Finance integration should report clinic cohorts the way the deal model assumed them, so a gap shows up in quarter two rather than in an impairment test.

Scale without proof is a pattern, not a healthcare quirk. Rentokil’s Terminix deal and Forward Air’s purchase of Omni show the same gap between the integration plan and the operating reality.

Prove the unit, split the price, build the capability, then buy the next platform.

For emerging managers: The Charter Program

Walgreens could absorb billions of write-downs and still find a buyer. A Fund I, II or III manager cannot. The discipline missing here is what a larger firm’s corporate development and integration teams provide, and emerging managers rarely have either in house.

The Charter Program is built for that gap: build the capabilities of a larger private equity firm without building the cost structure of one.

Origination carries no monthly retainer; Xpertegic earns a success fee at close and reinvests 10-20% of that fee into the platform. Diligence and integration are scoped and billed separately. Three managers are admitted in year one, starting with a pre-application.

Together these form an end-to-end M&A capability that lets a sponsor test each add-on before it buys the next.

Sources

1. CNBC, Walgreens strikes deal to open hundreds of doctor offices in stores, July 8, 2020
2. Walgreens Boots Alliance, Release on the $5.2 billion VillageMD investment (Form 8-K exhibit), October 14, 2021
3. Healthcare Dive, VillageMD to buy Summit Health for $8.9B with Walgreens and Evernorth support, November 2022
4. Private Equity Wire, Warburg Pincus exits Summit Health-CityMD in $8.9bn sale to VillageMD
5. Walgreens Boots Alliance, Form 10-Q, Q1 fiscal 2024, acquisitions note (Summit purchase accounting)
6. Walgreens Boots Alliance, Form 10-K, fiscal 2024, acquisitions note (VillageMD purchase accounting)
7. GloBest, Walgreens closing 160 VillageMD outlets, April 4, 2024
8. Walgreens Boots Alliance, Fourth quarter and fiscal 2024 results, October 2024
9. Walgreens Boots Alliance, Second quarter fiscal 2025 results, April 2025
10. Sycamore Partners, Sycamore completes acquisition of Walgreens Boots Alliance, August 28, 2025
11. Levin Associates, Harbor Health acquires 32 VillageMD health clinics, September 22, 2025
12. Bloomberg Law, Walgreens investors advance part of VillageMD partnership suit, January 2026
13. Forbes, VillageMD sells another 27 clinics to Harbor Health, October 6, 2026